A detailed history of Black Rock Inc. transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 4,798,522 shares of FULC stock, worth $22.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,798,522
Previous 1,541,209 211.35%
Holding current value
$22.5 Million
Previous $14.5 Million 104.48%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$5.98 - $9.31 $19.5 Million - $30.3 Million
3,257,313 Added 211.35%
4,798,522 $29.8 Million
Q1 2024

May 10, 2024

SELL
$6.7 - $12.0 $138,401 - $247,884
-20,657 Reduced 1.32%
1,541,209 $14.5 Million
Q4 2023

Feb 13, 2024

BUY
$3.18 - $6.86 $368,651 - $795,266
115,928 Added 8.02%
1,561,866 $10.5 Million
Q3 2023

Nov 13, 2023

SELL
$3.25 - $6.08 $222,582 - $416,400
-68,487 Reduced 4.52%
1,445,938 $6.42 Million
Q2 2023

Aug 11, 2023

SELL
$2.26 - $3.8 $6.03 Million - $10.1 Million
-2,669,313 Reduced 63.8%
1,514,425 $5 Million
Q1 2023

May 12, 2023

BUY
$2.83 - $13.99 $2.59 Million - $12.8 Million
914,747 Added 27.98%
4,183,738 $11.9 Million
Q4 2022

Feb 13, 2023

BUY
$5.01 - $8.35 $2.49 Million - $4.15 Million
496,647 Added 17.91%
3,268,991 $23.8 Million
Q3 2022

Nov 14, 2022

BUY
$4.92 - $9.1 $580,392 - $1.07 Million
117,966 Added 4.44%
2,772,344 $22.4 Million
Q2 2022

Aug 12, 2022

BUY
$4.2 - $24.0 $1.79 Million - $10.2 Million
425,768 Added 19.1%
2,654,378 $13 Million
Q1 2022

May 12, 2022

BUY
$9.96 - $23.65 $204,498 - $485,581
20,532 Added 0.93%
2,228,610 $52.7 Million
Q4 2021

Feb 10, 2022

BUY
$14.0 - $28.44 $2.48 Million - $5.04 Million
177,205 Added 8.73%
2,208,078 $39.1 Million
Q3 2021

Nov 09, 2021

BUY
$7.28 - $30.97 $5.34 Million - $22.7 Million
733,428 Added 56.53%
2,030,873 $57.3 Million
Q2 2021

Aug 11, 2021

BUY
$8.09 - $12.0 $10.5 Million - $15.6 Million
1,297,445 New
1,297,445 $13.6 Million

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $244M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.